About ArsenalBio
ArsenalBio is a company based in San Francisco (United States) founded in 2019 by Ken Drazan. ArsenalBio has raised $631.16 million across 3 funding rounds from investors including Kleiner Perkins, T. Rowe Price and University of California. The company has 178 employees as of December 31, 2022. ArsenalBio offers products and services including AB-4000 Series. ArsenalBio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 178 as on 31 Dec, 2022
- Founders Ken Drazan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arsenal Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$631.16 M (USD)
in 3 rounds
-
Latest Funding Round
$325.35 M (USD), Series C
Jul 09, 2024
-
Investors
Kleiner Perkins
& 22 more
-
Employee Count
178
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ArsenalBio
ArsenalBio offers a comprehensive portfolio of products and services, including AB-4000 Series.
Advanced T cell therapies designed to target and treat solid tumors effectively.
People of ArsenalBio
Unlock access to complete
Unlock access to complete
Funding Insights of ArsenalBio
ArsenalBio has successfully raised a total of $631.16M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $325.35 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ArsenalBio
ArsenalBio has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, T. Rowe Price and University of California.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital is invested in biopharmaceutical and healthcare firms.
|
Locked | Locked | Locked |
Investor details for ArsenalBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ArsenalBio
Investment portfolio details for ArsenalBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ArsenalBio
Detailed financials for ArsenalBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arsenalbio Comparisons
Peer comparison for ArsenalBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ArsenalBio
ArsenalBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of ArsenalBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arsenalbio
Complete news archive for ArsenalBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArsenalBio
ArsenalBio was founded in 2019.
ArsenalBio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ken Drazan is the current CEO of ArsenalBio. They have also founded this company.
ArsenalBio is a funded company, having raised a total of $631.16M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at ArsenalBio is 178.
Developer of immune cell therapies. The company develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies.
ArsenalBio's top competitors include Moderna, BeiGene and Juno Therapeutics.
ArsenalBio offers AB-4000 Series.
ArsenalBio has 23 investors. Key investors include Kleiner Perkins, T. Rowe Price, University of California, Arch Venture Partners, and Bristol-Myers Squibb.